ReviewSynthetic and systems biotechnology2026
Harnessing synthetic biology for tetraterpenoid astaxanthin production: Recent advances and challenges.
Review in Synthetic and systems biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Engineering Microalgae for Enhanced Astaxanthin Production: Integrating Metabolic Pathways and Nano-Biotechnologies.Marine drugs · 2025Review
- Beyond pigments and perfumes: engineering in the carotenoid and apocarotenoid spectrum, novel enzymes, and synthetic biology strategies.Frontiers in bioengineering and biotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astaxanthin, a potent lipid-soluble ketocarotenoid, exists in various stereoisomeric, geometric isomeric, and esterified forms. Its unique molecular configuration and biological activity confer significant advantages for pharmaceutical applications and nutraceutical supplementation. While widely distributed in natural environments, particularly abundant in marine ecosystems, astaxanthin production via conventional methods fails to meet escalating market demands and consumer preference for natural products. Recent synthetic biology advances enable engineered microbial cell factories for astaxanthin production. Through precise genome editing and metabolic reprogramming, these systems offer a sustainable, efficient alternative to traditional synthesis of this high-value antioxidant. In this review, we highlight the latest advancements in constructing artificial cell factories for the production of astaxanthin. Specially, we systematically examine current breakthroughs in synthetic biology-enabled astaxanthin manufacturing, with emphasis on three dimensions: "point" (regulation of key enzymatic activity and expression levels), "line" (pathway-level spatial coordination to balance intermediate flux), and "plane" (system-level metabolic harmonization to address product toxicity and pathway-host metabolic incompatibility). We further discuss critical gaps requiring interdisciplinary innovation to realize the full potential of microbial cell factories in sustainable astaxanthin manufacturing production.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.